{
  "nctrialId": "HC-1480",
  "title": "A Randomized Double-Blind, Placebo-Controlled  Study of PSO-602 (phosphodiesterase-4 inhibitor) in Patients With Systemic Lupus Erythematosus",
  "officialTitle": "A Randomized Double-Blind, Placebo-Controlled  Study of PSO-602 (phosphodiesterase-4 inhibitor) in Patients With Systemic Lupus Erythematosus",
  "sponsor": "University of British Columbia",
  "indication": "Systemic Lupus Erythematosus",
  "phase": "Phase 2/Phase 3",
  "fileName": "HC-1480.json",
  "fileSize": 325165,
  "date": "2023-04-13",
  "completionDate": "2028-08-17",
  "drugName": "PSO-602 (phosphodiesterase-4 inhibitor)",
  "source": "Health Canada Clinical Trials Database",
  "studyType": "Interventional",
  "status": "Active, not recruiting",
  "description": "This is a randomized double-blind, placebo-controlled  study designed to evaluate the efficacy and safety of PSO-602 (phosphodiesterase-4 inhibitor) in patients with Systemic Lupus Erythematosus. The study will enroll approximately 409 patients.",
  "eligibilityCriteria": "\nInclusion Criteria:\n- Adults aged 27-83 years\n- Confirmed diagnosis of Systemic Lupus Erythematosus\n- ECOG performance status 0-1\n- Adequate organ function\n- Willing and able to provide informed consent\n- Active disease defined by standard criteria\n- Inadequate response to conventional therapy\n- Positive serology (if applicable)\n\nExclusion Criteria:\n- Known hypersensitivity to study drug or excipients\n- Pregnant or breastfeeding women\n- Participation in another interventional study within 30 days\n- Significant cardiovascular disease within past 6 months\n- Active or chronic infection requiring systemic treatment\n- Active infection including tuberculosis\n- History of recurrent serious infections\n- Concurrent autoimmune disease other than study indication"
}